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OBJECTIVE. We studied the feasibility and the effectiveness of percutaneous etha-
nol Injection, performed with general anesthesia In a single session, for treating
malignant hepatic lesions.
SUBJECTS AND METHODS. We treated 30 patients with sonographically guided
percutaneous injection of ethanol. Twenty had hepatocellular carcinoma and clrrho-
sis, and 10 had hepatic metastases, principally from colon cancer. The mean volume
of ethanol injected was 57 ml (range, 6-165 ml).
RESULTS. CT showed complete necrosis (up to 8.2 cm) In seven of 10 patIents with
encapsulated hepatocellular carcinoma and about 90% necrosIs in the remaining
three patients. In four of these patients, the ct-fetoprotein level fell from more than 200
ng/ml to less than 20 ng/ml during treatment. In 10 patients with Infiltrating hepatocel-
lular carcinoma, about 70-90% necrosIs was achieved; in six of these patients, the a-
fetoprotein level, which had been more than 200 ng/ml, decreased during treatment.
In the 10 patients with metastases, more than 50% necrosIs was always achieved.
Levels of carcinoembryonlc antigen decreased after treatment in all patients. In three
patients who had cirrhosis with superficial hepatocellular carcinoma, peritoneal hem-
orrhage occurred but did not require transfusion.
CONCLUSION. Our results show that percutaneous injection of ethanol in a single
session with general anesthesia Is feasible and effective and has several advantages
over multlsesslon therapy. These Include shorter treatment time and the ability to
treat larger and more numerous lesions.
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Percutaneous ethanol injection (PEI) under sonognaphic guidance has been
shown to improve the survival of patients with hepatocellular carcinoma (HCC)
and cirrhosis whose tumors are less than 5 cm in diameter [1-5]. The effective-
ness of PEI in treating hepatic metastases has yet to be proved [6]. Treatment is
usually given in an outpatient setting, twice weekly in three to 15 sessions,
depending on the number of lesions and their size, in doses of only a few milliliters
in order to avoid severe pain. For treatment with PEI, most researchers select
patients with no more than three lesions, each with a diameter less than 3-5 cm.
To see whether PEI is feasible for treating patients with larger and more numerous
lesions, even for palliative treatment, we conducted a feasibility trial of PEI in a
single session with general anesthesia.
Subjects and Methods
Subjects
Thirty patients were treated, 20 patients with HCC and cirrhosis and 10 patients with
hepatic metastases.
The patients with HCC included 16 men and four women from 32 to 75 years old (mean,
65 years old). Nineteen patients had disease classified as Child’s class A and one had class
B disease. Patients were selected because they could not have surgery and had lesions
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larger than 5 cm in diameter on multiple lesions. Four patients with a
solitary tumor smaller than 5 cm in diameter were treated in a single
session because they refused the standard method. Patients with
prothrombin activity less than 40% on a platelet count less than
40,000/mm3 were excluded. Diagnosis was based on results of
sonographically guided fine-needle biopsy in 10 patients and on a-
fetoprotein levels that were greater than 200 ng/mi when imaging
studies showed that the lesion was consistent with HCC in the oth-
ens. imaging showed that 10 patients had a single lesion ranging
from 2.3 to 10.0 cm in diameter (mean, 5.7 cm), and 10 patients had
from two to five lesions each (for a total of 37 lesions) ranging from
0.9 to 8.0 cm in diameter (mean, 3.1 cm). Eight of the patients with
multiple lesions had already received standard treatment with PEI;
three of these patients had lesions that were recurrences due to
incomplete treatment and the others had new lesions. a-Fetoprotein
levels were more than 200 ng/mi in 10 of the 20 patients with HCC.
Patients with metastases included six men and four women, 48 to
81 years old (mean, 63 years old). Patients were selected because
they could not have on refused surgery. Diagnosis was based on
results of sonographicaiiy guided fine-needle biopsy in four patients
and on levels of carcinoembryonic antigen that were greater than 5
ng/mI when imaging studies showed that the lesions were compati-
ble with metastases and the lesions had not been present on the
previous images. The primary tumor, resected in all cases, was of
the colon or rectum in eight patients, of the breast in one patient,
and of the gallbladder in one patient. Imaging studies showed that
four patients had a single lesion ranging from 2.8 to 5.7 cm in diam-
eter (mean, 4.7 cm), five had from two to four lesions each (for a
total of 15 lesions) ranging from 1.1 to 5.8 cm in diameter (mean,
3.2 cm), and one had confluent lesions occupying 40% of the
hepatic parenchyma. Levels of carcinoembryonic antigen were
more than 5 ng/ml in all patients with metastases from the gas-
trointestinal tract.
in all patients, aspartate aminotransfenase (AST), alanine ami-
notransferase (ALT), alkaline phosphatase, bilirubin, amylase, and
hemoglobin levels, prothrombin time, platelet count, and RBCs and
WBCs were evaluated before PEI.
Technique
We used a commercially available sonognaphy scanner with a
3.5-MHz convex probe and guide attachment or with a 3.5-MHz un-
ear probe that had an incorporated guide. Two types of needles
were used to instill the ethanol: a 22-gauge spinal needle (Becton-
Dickinson, Rutherford, NJ) and a 21-gauge needle with closed coni-
cal tip and three terminal side-holes (Hakko, PElT needle, Tokyo,
Japan). As a rule, the spinal needle was used for lesions smaller
than 3 cm or for small areas left unperfused by the muitihole needle,
and the other needle was used for the other lesions.
The procedure was performed with general anesthesia, endotra-
cheal intubation, and mechanical ventilation. This kind of anesthesia
is well suited for this procedure because it allows periods of con-
trolied apnea on respiratory standstill with partial pulmonary inflation
as requested. At the start of PEI, 20 patients received fructose-i 6-
diphosphate (Esafosfina, Biomedica Foscama, Ferentino, Italy)
i000-i500 mg and glutathione-SH (TAD 600, Biomedica Foscama,
Rome, Italy) 1200 mg IV drip in 30 mm with the aim of neutralizing
the toxic systemic effects of injected alcohol by speeding up its
metabolism. Blood alcohol level was measured immediately after
treatment and 2 hr and 24 hr later. Depending on the site of the
lesion, patients were placed supine or in a left lateral decubitus posi-
tion. Patients received three to 22 (mean, 12) injections of sterile
95% ethanol (SALE, Bengamo, Italy), depending on the size of the
lesion and the mode of perfusion, until perfusion of the lesion was
presumed to be complete, that is, until the entire lesion appeared to
be more echogenic than the surrounding tissue at sonography (Fig.
i). Care was taken to inject the deepest portions of the lesion first,
then the central and finally the superficial portions, in order to pro-
vent superficial spillage of ethanol from masking the view for subse-
quent injections. Ethanol was injected slowly (1 ml in 5-iO sec) and
its diffusion was monitored with real-time sonography. As long as
the ethanol was seen to disappear rapidly from the needle tip, injec-
tion was continued until ethanol pooled in the lesion.
Follow-up Studies
AST, ALT, alkaline phosphatase, bilirubin, amylase, and hemoglo-
bin levels, prothrombin time, platelet count, and RBCs and WBCs
were evaluated 2 hr, 24 hr, 48 hn, and 10 days after PEI. Levels of
tumoral markers (a-fetoprotein and cancinoembryonic antigen) were
measured and sonography and CT were performed 1 month after
treatment. Long-term follow-up ranged from 6 to 18 months (mean,
iO.5 months). Follow-up controls consisted of (i) sonography, mea-
sunement of levels of tumor markers, and liver function tests every 3
months and (2) unenhanced and contrast-enhanced CT every 6
months. in all patients, contiguous, 1-cm-thick sections were
imaged. lopamidol (lopamiro 300, Bracco, Milan, Italy) was adminis-
tened as a 100-mi bolus (2-3 mI/sec) followed by a rapid infusion of
Fig. 1.-Single, encapsulated lesion of
hepatocellular carcinoma In left lobe, 6.2 cm In
diameter.
A, Transverse sonogram obtained before
percutaneous Injection of ethanol (PEI) shows
lesion (cursors) of mixed echogenicity.
B, Sonogram obtained just after slngle-ses-
slon PEI (80 ml in 16 InjectIons) shows lesion
homogeneously perfused by ethanol, without
extravasatlon.
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50-100 ml, depending on body weight. Scanning began 30 sec after
the start of contrast administration. Additional 5-mm-thick sections
were imaged when more precise details were needed. We rated the
response to treatment as complete when the CT scans showed no
aneas of enhancement within the lesion 1 month after treatment,
when this finding was confirmed in the follow-up scans, and when
the CT scans and sonograms showed no increase in tumor volume.
We did not use the serologic measurements of tumor marker levels
to assess response to treatment because those levels can return to
normal when the scans do not show complete response (due to
near-total necrosis of the tumor tissue) or decrease even when the
scans do show complete response (due to the presence of intrahe-
patic or extrahepatic lesions that were not detected or were undo-
tectable). We rated the response as partial when the CT scan
showed more than 50% necrosis and the tumor marker levels had
decreased.
Results
The total volume of alcohol administered per patient
ranged from 6 to 165 ml (mean, 57 ml). The smaller amount
was given to a patient with a single HCC 2.3 cm in diameter,
and the greatest amount was given to a patient with conflu-
ent metastatic lesions occupying 40% of the hepatic paren-
chyma. Time required for the instillation of alcohol was 20-
50 mm (mean, 30 mm). The average hospital stay was 2.2
days for patients with metastases and 2.9 days for those
with HCC. During the 3-4 days after treatment, 26 patients
had tenderness in the night hypochondnium and 1 2 had
hyperpyrexia (38-38.5#{176}C); hyperpyrexia developed in
patients who received more than 50 ml of alcohol.
Transient mild changes in the results of liver function
tests, in particular an increase in tnansaminase levels, were
observed in all but two cases. The highest level of AST was
868 U/i (normal, 5-35 U/I) and of ALT was 770 U/i (normal,
7-56 U/I). The increase in transaminase level was directly
correlated with tumor volume and consequently with the
quantity of ethanol injected. In all cases, the transaminase
level returned to near the level before treatment in 10 days.
Blood alcohol levels immediately after treatment were 10-
229 mg/i 00 ml (mean, 82 mg/i 00 ml) and 2 hr later were 3-142
mg/100 ml (mean, 47 mg/mI). In all patients, the values returned
to normal within 24 hr. The time required for serum levels of eth-
anol to return to normal was not appreciably different between
patients who were treated with drugs during PEI and those who
were not, but the former regained consciousness more easily
and quickly. From the day after treatment, imaging examina-
tions showed gas formation within the lesions in about 80% of
patients, which was recognizable for 3-1 5 days.
Some complications occurred. Three patients with superfi-
cially located HCCs, without a cuff of normal hepatic paren-
chyma between the liven capsule and the lesion, had bleeding
into the pentoneum. In all patients, the decrease in hemoglo-
bin level was minimal (2 g%) and did not require transfusion.
Two patients with HCC had necrosis of nonneoplastic tissue
adjacent to the tumor with a marked increase in transaminase
levels (AST, 1580 and 1341 U/L; ALT, 2263 and 1819 U/L);
these patients had pain lasting 2-3 days that required analge-
Sics (Fig. 2). In two patients with HCC, sonograms obtained 1
month after ethanol injection showed thrombosis of a seg-
mental portal vein tributary to the tumor; this finding disap-
peaned spontaneously 3 months after treatment.
Follow-up of Hepatomas
Seven of the 1 0 patients who had an encapsulated lesion
had complete response, and three had about 90% necrosis
(Figs. 3 and 4). One of the latter patients underwent two
additional injections with standard PEI, after which response
was complete. All complete responses observed after treat-
ment were confirmed during follow-up. One patient with an
encapsulated lesion 3.4 cm in diameter who showed com-
plete response on imaging studies underwent liven trans-
plantation 6 months later, which revealed 100% necrosis of
the neoplastic tissue. In patients with infiltrating lesions,
necrosis was extensive (-70-90%), although it could not be
evaluated precisely with imaging studies. Elevated (z-feto-
protein levels in the four patients with an encapsulated
lesion returned to normal in all cases: from 21 7, 51 0, 2340,
and 2870 ng/ml to less than 20 ng/ml. Elevated a-fetoprotein
levels in the six patients with infiltrating lesions decreased
in all cases: from 246, 320, 955, >3000, >3000, and 5640
Fig. 2.-Hepatlc necrosis from extravasa-
tlon of ethanol.
A, Contrast-enhanced CT scan shows low
density of sixth hepatic segment, with gas for-
matlon In nonneoplastic parenchyma. This pat-
tern, due to hepatic necrosis after extravasatlon
of ethanol from a lesion in fIfth segment, was ac-
companled by abdominal pain and a significant
transient Increase In transamlnase level.
B, CT scan obtained after 6 months of treat-
ment shows well-defined area of low density
(17 H).
treatment. Three months after treatment, one patient died of
liven failure caused by obstructive jaundice due to hilan meta-
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Fig. 3.-Single, encapsulated hepatocellular
carcinoma, 5.6 cm In diameter.
A, CT scan obtained before treatment shows
Inhomogeneous area of high density (69-87 H).
B, CT scan obtained I day after treatment (60
ml In 12 InjectIons) shows gas formation within
lesion.
C and D, After I 2 months, complete re-
sponse is confirmed. Lesion shows no en-
hancement: density is same on unenhanced CT
scan(C, 35 and 42 H)and on contrast-enhanced
CT scan (D, 24 and 43 H). Level of a-fetoprotein
before percutaneous Injection of ethanol was
2870 ng/ml; 1 month and 1 2 months after treat-
ment, level had returned to normal (<20 nglml).
Fig. 4.-Single, encapsulated hepatocellular carcinoma, 4.5 cm In diameter.
A, Contrast-enhanced CT scan obtained before percutaneous Injection of ethanol (PEI) shows lesion.
B, CT scan obtained 1 month after single-session PEI (50 ml In 13 injections) shows partial response to treatment. Small area of high density that
remains at periphery of lesion represents neoplastlc tissue.
C, Sonogram shows same viable area (cursor), which was subsequently treated with two additIonal percutaneous Injections of ethanol by standard
technique, yielding a complete response.
ng/mi to 79, 60, 396, 260, 568, and 1 500 ng/ml, respectively.
During follow-up, new lesions were detected in two patients
6 months after treatment and in one patient 3 months after static lymphadenopathy.
AJR:161, November 1993 PERCUTANEOUS ETHANOL INJECTION OF LIVER TUMORS 1069
Follow-up of Metastases
The response evaluated by imaging was partial, around
60-80%, in all patients. No complications occurred. Levels of
carcinoembryonic antigen, measured 1 month after treatment,
decreased in all patients: from 13, 30, 70, 83, 156, 188, 226,
and 1396 ng/mI to 9, 18, 8, 27, 42, 108, 35, and 560 ng/ml,
respectively. Dunng follow-up, new hepatic lesions on local
recurrences were detected in all patients. One patient died of
his underlying disease 9 months after treatment.
Discussion
The rationale for the use of PEI in HCC is based on the fol-
lowing tenets: sonognaphic screening of patients with cirrhosis
allows detection of tumors that are relatively small and confined
to the liver; the difference in density between the soft neoplastic
tissue and the hand cirrhotic tissue around it allows alcohol to
diffuse easily throughout the tumor without extravasating into
liver tissue; highly concentrated injection of alcohol causes
intratumoral arterial thrombosis followed by tumoral ischemia;
PEI spares liven tissue surrounding the HCC; and PEI is safer
than surgery, which carries a higher risk of mortality and morbid-
ity. In the treatment of small HCCs, PEI now has a well-defined
role, with a 3-year survival rate similar to that for surgery [7].
Until recently, PEI has been used to treat only lesions that
are less than 5 cm in diameter; it was thought that larger lesions
would require an inordinate number of injections and hence an
unduly long course of treatment, with no guarantee that the
whole lesion would be treated. With the single-session tech-
nique, we aimed to expand the use of PEI to larger and more
numerous lesions (avoiding at the same time some disadvan-
tages such as pain and long treatment times). Although single-
session PEI started as a purely palliative technique, the results
were unexpectedly good in encapsulated lesions, suggesting a
more long-term response in these cases. In fact, complete
response was obtained even with large tumors up to 8.2 cm in
diameter, as confirmed at 1-year follow-up. In infiltrating HCC,
the single-session technique enabled massive but not always
complete necrosis with a transient decrease in a-fetoprotein
levels. For infiltrating on multicentnc tumors, in which surgery is
contraindicated, intraarterial therapy in some form is usually
given. The amount of necrosis achievable with these methods
is unpredictable, with a mean response of about 45% [8]. Con-
sidenng the degree of necrosis obtained with the single-session
technique in this study, we believe that this method could be
offered as an alternative to intraarterial therapy. We now treat
all patients with multiple lesions on single lesions greaten than 5
cm in diameter with single-session PEI. Those with small soli-
tary lesions are treated by the traditional approach to obviate
general anesthesia.
The rationale for the use of PEI in hepatic metastases
includes the assumption that destruction of the greatest possi-
ble quantity of neoplastic tissue should prolong survival. How-
ever, the role of PEI is not yet clean. Complete responses
have been obtained only in patients with small endocrine
metastases; in most other patients, with metastases from
colon cancer greater than 3 cm in diameter, responses were
almost always partial [6]. Considenng the long time it takes to
treat those patients, most of whom have multiple lesions, and
the uncertainty of the outcome, our aim with the single-ses-
sion technique was to make treatment more rapid, less pain-
ful, and therefore more acceptable. The response was only
partial, with necrosis greater than 50% and only a transient
decrease in levels of carcinoembryonic antigen. Necrosis was
incomplete even in the smaller lesions, in contrast to previous
reports with the standard PEI technique [6]. As metastases
from colon cancer are often not encapsulated, alcohol pene-
trates the liver tissue, making further injections difficult.
Because this problem is less apparent when the standard
method is used, with its smaller quantity of ethanol injected,
all our patients with inoperable metastases greaten than 4 cm
in diameter (whether single on multiple) receive the single-ses-
sion treatment, while those with a single lesion less than 3 cm
in diameter are still treated with the standard procedure.
Some complications occurred in patients with cirrhosis and
HCC. Necrosis of nonneoplastic hepatic tissue, due to
extravasation of ethanol, was not foreseeable but does not
seem to have been a major problem for patients (the only
complaint was pain). However, because liven function is tran-
siently impaired in these patients, advanced cirrhosis might be
a contraindication for the single-session technique. Penitoneal
hemorrhage, which occurred in three patients with superficial
lesions, did not require further treatment. Only one case of
major penitoneal hemorrhage has been reported [4]. The
bleeding that occurred in our patients was probably due to the
sum of small amounts of bleeding from the numerous small
injuries caused by needle insertion made on the liver surface.
Chemical thrombosis of the segmental portal vein tributary to
the lesion has sometimes been reported in the PEI series, but
without related problems [2, 6]. We were even more prepared
for this to occur after the single-session technique because of
the larger dose of alcohol, but as in the reported cases, the
thrombosis disappeared spontaneously in our patients.
We conclude that single-session PEI is feasible, is accept-
able to patients, and in some cases yields excellent long-
term results. Nevertheless, the complications that occurred
in some patients with cirrhosis prompt caution. More expeni-
once is needed before the indications for this procedure can
be cleanly defined.
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